Miochol-E 10 mg/ml jauhe ja liuotin instillaatioliuosta varten, silmän sisään فنلندا - الفنلندية - Fimea (Suomen lääkevirasto)

miochol-e 10 mg/ml jauhe ja liuotin instillaatioliuosta varten, silmän sisään

dr. gerhard mann chem.-pharm. fabrik gmbh - acetylcholine chloride - jauhe ja liuotin instillaatioliuosta varten, silmän sisään - 10 mg/ml - asetyylikoliini

Ketosteril tabletti, kalvopäällysteinen فنلندا - الفنلندية - Fimea (Suomen lääkevirasto)

ketosteril tabletti, kalvopäällysteinen

fresenius kabi ab - histidine, lysine acetate, threonine, tryptophane, tyrosine, alpha-ketoleucine calcium, alpha-ketophenylalanine calcium, alpha-ketovaline calcium, d,l-alpha-hydroxymethionine calcium, d,l-alpha-ketoisoleucine calcium - tabletti, kalvopäällysteinen - aminohapot

Ultomiris الاتحاد الأوروبي - الفنلندية - EMA (European Medicines Agency)

ultomiris

alexion europe sas - ravulizumab - hemoglobinuria, paroxysmal - selektiiviset immunosuppressantit - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Vyvgart الاتحاد الأوروبي - الفنلندية - EMA (European Medicines Agency)

vyvgart

argenx - efgartigimod alfa - myasthenia gravis - immunosuppressantit - vyvgart is indicated as an add on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gmg) who are anti acetylcholine receptor (achr) antibody positive.

Oriprim vet jauhe فنلندا - الفنلندية - Fimea (Suomen lääkevirasto)

oriprim vet jauhe

orion corporation - sulfadiazine, trimethoprim - jauhe - sulfadiatsiini ja trimetopriimi

Reodyn 50 mg/ml oraaliliuos فنلندا - الفنلندية - Fimea (Suomen lääkevirasto)

reodyn 50 mg/ml oraaliliuos

orion corporation - carbocysteine - oraaliliuos - 50 mg/ml - karbosisteiini

Mesalazin Orion 500 mg enterotabletti فنلندا - الفنلندية - Fimea (Suomen lääkevirasto)

mesalazin orion 500 mg enterotabletti

faes farma, s.a. - mesalazine - enterotabletti - 500 mg - mesalatsiini

Mesalazin Orion 1000 mg enterotabletti فنلندا - الفنلندية - Fimea (Suomen lääkevirasto)

mesalazin orion 1000 mg enterotabletti

faes farma, s.a. - mesalazine - enterotabletti - 1000 mg - mesalatsiini